BioNTech SE
- Jurisdiction
Germany - LEI
894500UZJ5LG1F8J1U58 - ISIN
US09075V1026 (BNTX )- Sectors
Scores
- Fair value (Benjamin Graham formula)
- N/A
- Financial strength (Piotroski F-Value)
-
6
/ 9
- Fundamental strength relative to industry (Mohanram G-Value)
-
4
/ 7
Profile
BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. Read full profile
Stock price
Fundamentals
- Net revenue
€2.86B - Gross margin
79.7% - EBIT
-€876.10M - EBIT margin
-30.6% - Net income
-€347.44M - Net margin
-12.1%
Statement period: - (published )
Estimates
| Fiscal Year | Net revenue | Net income |
|---|---|---|
|
|
| |
|
|
| |
|
|
|
Dividends
- Last dividend amount
-
$2.11 - Ex date
-
- Payment date
-
Congress transactions
| Name | Transaction date | Value |
|---|---|---|
| Val Hoyle | September 12, 2025 | $1.00K–$15.00K |
| Josh Gottheimer | October 3, 2024 | $1.00K–$15.00K |
| Josh Gottheimer | September 11, 2024 | $1.00K–$15.00K |
Analyst ratings
4 analysts rated this company in the past 90 days. The average target price is €116.12, this is a change of +29.7% compared to the current price.
Investor transactions
| Name | Shares | Value | Last change | Change type |
|---|---|---|---|---|
| James Anderson |
|
|
|
Sell |
| Andreas Halvorsen |
|
|
|
Sell |
| Ray Dalio |
|
|
|
Sell |